Technical indicators have turned bullish for Dexcom, Bristol Myers Squibb, and Quanta Services, three stocks Barron's previously flagged as picks, according to a Sept. 2 follow-up review. The three names span medical devices, pharmaceuticals, and infrastructure services.
A Barron's follow-up review published Sept. 2 has flipped its technical read on Dexcom, Bristol Myers Squibb, and Quanta Services to bullish, a shift from the charts the publication flagged in an earlier round of stock picks.
The reassessment, written by Barron's technical analyst Doug Busch, reflects improving momentum across all three names. Barron's Investor Circle, the publication's stock-selection service, uses technical analysis to time entries and exits on individual stocks rather than to forecast broad index direction.
The three companies span unrelated sectors. Dexcom, a medical-device maker trading on the Nasdaq under DXCM, builds continuous glucose monitors used by people with diabetes. Bristol Myers Squibb, listed on the New York Stock Exchange as BMY, is a pharmaceutical company whose portfolio includes cancer immunotherapy Opdivo and blood thinner Eliquis. Quanta Services, trading as PWR, provides engineering and construction services to the electric-power and energy industries.
For technical traders, a bullish signal typically reflects a combination of moving-average crossovers, momentum oscillators, and price breaking above prior resistance levels. The review did not disclose the specific indicator readings behind each call, and the three setups carry different risk profiles given their distinct business cycles.
The follow-up matters because it supports the original thesis for investors who acted on the earlier picks. Dexcom faces competitive pressure in the glucose-monitoring market, Bristol Myers is navigating patent expirations on key drugs, and Quanta is tied to the pace of grid and renewable-energy spending. Each stock's next catalyst — earnings, product news, or infrastructure contract awards — will test whether the bullish technical momentum holds.
This article is for informational purposes only and does not constitute investment advice.
